Oak Ridge Investments LLC Has $1.10 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Oak Ridge Investments LLC lessened its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 3.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,945 shares of the company’s stock after selling 472 shares during the quarter. Oak Ridge Investments LLC’s holdings in Axsome Therapeutics were worth $1,095,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth about $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Axsome Therapeutics during the second quarter valued at approximately $47,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares in the last quarter. Moors & Cabot Inc. bought a new position in Axsome Therapeutics in the third quarter valued at approximately $200,000. Finally, Whalen Wealth Management Inc. acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth approximately $236,000. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Down 1.9 %

Shares of AXSM opened at $91.93 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $105.00. The firm’s 50 day moving average is $92.27 and its 200-day moving average is $89.46.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter last year, the company earned ($1.32) EPS. On average, analysts expect that Axsome Therapeutics, Inc. will post -4.61 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on AXSM shares. Needham & Company LLC reissued a “buy” rating and issued a $133.00 target price on shares of Axsome Therapeutics in a research note on Monday, January 13th. Royal Bank of Canada boosted their price objective on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $121.00 target price on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Truist Financial boosted their price target on Axsome Therapeutics from $150.00 to $180.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $130.69.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.